Search results for "Pneumococcal Vaccines"

showing 10 items of 29 documents

Factors associated with influenza vaccination of hospitalized elderly patients in Spain

2016

Vaccination of the elderly is an important factor in limiting the impact of influenza in the com- munity. The aim of this study was to investigate the factors associated with influenza vacci- nation coverage in hospitalized patients aged 65 years hospitalized due to causes unrelated to influenza in Spain. We carried out a cross-sectional study. Bivariate analysis was performed comparing vaccinated and unvaccinated patients, taking in to account sociodemographic variables and medical risk conditions. Multivariate analysis was per- formed using multilevel regression models. We included 1038 patients: 602 (58%) had received the influenza vaccine in the 2013 - 14 season. Three or more general p…

RNA virusesMaleViral Diseaseslcsh:MedicineGlobal HealthPersones gransGeographical LocationsPneumococcal VaccinesElderlyMedicine and Health SciencesPublic and Occupational HealthVacunaciólcsh:SciencePathology and laboratory medicineAged 80 and overVaccinesVaccinationMedical microbiologyVaccination and ImmunizationEuropeInfectious DiseasesStreptococcus pneumoniaeInfluenza A virusInfluenza VaccinesVirusesFemalePathogensAssistència hospitalàriaResearch ArticleImmunologyMicrobiologyInfluenzavirusPatient Education as TopicInfluenza HumanHumansInfluenza virusesEspanyaAgedInpatientsHospital careMarital Statuslcsh:ROrganismsViral pathogensBiology and Life SciencesPneumonia PneumococcalInfluenzaMicrobial pathogensCross-Sectional StudiesSocial ClassAge GroupsSpainPeople and PlacesPopulation Groupingslcsh:QPreventive MedicineOlder peopleOrthomyxoviruses
researchProduct

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D…

2009

Background The choice of non-typeable Haemophilus influenzae Protein D as main carrier protein in the candidate 10-valent pneumococcal conjugate vaccine (PHiD-CV, GlaxoSmithKline Biologicals), was driven in part to avoid carrier-mediated suppression and possible bystander interference with coadministered vaccines. Immunogenicity data from 3 primary and 2 booster vaccination studies were assessed for possible impacts of PHiD-CV coadministration on immune responses to routinely administered childhood vaccines, in comparison to 7-valent pneumococcal conjugate vaccine (7vCRM) coadministration. Methods Randomized, controlled studies in which PHiD-CV or 7vCRM vaccines were coadministered with DTP…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineLipoproteinsImmunization SecondaryMeningococcal VaccinesBooster dosemedicine.disease_causeAntibodies Viralcomplex mixturesPneumococcal conjugate vaccineHaemophilus influenzaePneumococcal VaccinesBacterial ProteinsConjugate vaccineHeptavalent Pneumococcal Conjugate VaccineMedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicVaccines Conjugatebusiness.industryImmunization ProgramsDiphtheriaImmunogenicityVaccinationInfantImmunoglobulin Dmedicine.diseaseVirologyAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesTreatment OutcomePediatrics Perinatology and Child HealthImmunologybusinessCarrier Proteinsmedicine.drugThe Pediatric infectious disease journal
researchProduct

Pneumococcal conjugate vaccine for acute otitis media—yes or no?

2003

Vaccines ConjugateAcute otitis mediabusiness.industryInfantGeneral MedicinePneumococcal conjugate vaccinePneumococcal VaccinesOtitis MediaChild PreschoolAcute DiseaseImmunologymedicineHumansChildbusinessmedicine.drugThe Lancet
researchProduct

Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia.

2014

Although secondary hypogammaglobulinemia is more frequent than primary hypogammaglobulinemia, its etiology and management are poorly described, particularly for mild hypogammaglobulinemia.This retrospective observational study included all adult patients with a gammaglobulin level6.4g/L on serum electrophoresis identified at Dijon teaching hospital between April and September 2012. Clinico-biological features, etiologies and infectious complications were collected at inclusion and compared between group 1 (gammaglobulin5g/L, severe hypogammaglobulinemia), and group 2 (gammaglobulin6.4 and ≥5g/L, mild hypogammaglobulinemia).Among the 4011 serum electrophoreses, 570 samples from 389 patients …

ElectrophoresisMalePediatricsmedicine.medical_specialtyInfectionsSeverity of Illness IndexHypogammaglobulinemiaPneumococcal Vaccinesimmune system diseasesAgammaglobulinemiahemic and lymphatic diseasesSecondary HypogammaglobulinemiaInternal MedicinemedicineHumansAgedRetrospective StudiesAdult patientsbusiness.industryRetrospective cohort studyGamma globulinmedicine.diseaseElectrophoresesImmunologyEtiologyFemalebusinessEuropean journal of internal medicine
researchProduct

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination s…

2014

Streptococcus pneumoniae is a major cause of human infectious diseases worldwide. Despite this documented evidence, data on pneumococcal disease rates among general populations are scant because of the frequent lack of cultural identification. In this study we propose a model for estimating the burden of pneumococcal pneumonia on hospitalizations. The study was performed by analyzing administrative and clinical data of patients aged 50 years or older, resident in Sicily, and hospitalized, from 2005 to 2012. Demographic information, admission/discharge dates, discharge status, and up to 6 discharge diagnoses coded according to ICD-9 CM were collected for each hospitalized patient. During the…

MalePediatricsmedicine.medical_specialtyImmunologyPopulationSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causePneumococcal VaccinesCost of IllnessHealth careStreptococcus pneumoniaemedicineHumansImmunology and AllergyeducationSicilyAgedAged 80 and overPharmacologyeducation.field_of_studySicily Streptococcus pneumoniae hospitalizations model estimating pneumococcal pneumoniabusiness.industryVaccinationBudget impactMiddle AgedPneumonia Pneumococcalmedicine.diseaseHospitalizationVaccinationPneumoniaPopulation SurveillancePneumococcal pneumoniaFemaleDiagnosis codebusinessResearch PaperHuman Vaccines & Immunotherapeutics
researchProduct

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spa…

2013

Abstract Background Given the concurrent administration of multiple vaccines during routine pediatric immunizations, efforts to elucidate the potential interference of any vaccine on the immune response to the concomitantly administered antigens are fundamental to prelicensure clinical research. Methods This phase 3 randomized controlled trial of 13-valent pneumococcal conjugate vaccine (PCV13) versus 7-valent PCV (PCV7) assessed immune responses of concomitantly administered meningococcal group C conjugated to diphtheria toxin cross-reactive material 197 (MnCCV-CRM 197 ) in a 2-dose infant series and 15-month toddler dose. Results 619 subjects were randomized, 315 to PCV13 and 304 to PCV7.…

MaleHeptavalent Pneumococcal Conjugate VaccineMeasles-Mumps-Rubella VaccineDrug-Related Side Effects and Adverse ReactionsMeningococcal VaccinesPneumococcal conjugate vaccinePneumococcal VaccinesConjugate vaccineMedicineHumansToddlerImmunization ScheduleGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityVaccinationPublic Health Environmental and Occupational HealthAntibody titerInfantAntibodies BacterialHealthy VolunteersTiterInfectious DiseasesTolerabilitySpainImmunologyMolecular MedicineFemalebusinessmedicine.drugVaccine
researchProduct

Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipien…

2009

The current recommendations for active immunization after stem cell transplant (SCT) include 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7) from 3 months after transplant, followed by a 23-valent polysaccharide pneumococcal vaccine (PPV23). However, until now, the immune response to PPV23 after PCV7 has not been assessed after SCT. In the EBMT IDWP01 trial, 101 patients received 1 dose of PPV23 at 12 or 18 months, both after 3 doses of PCV7. The efficacy of PPV23 was assessed 1 month later and at 24 months after transplant by the pneumococcal serotype 1 and 5 antibody levels. Serotype 1 and 5 are not included in PCV7. Although the geometric mean concentrations were significantly …

SerotypeAdultMaleHeptavalent Pneumococcal Conjugate VaccineAdolescentActive immunizationcomplex mixturesPneumococcal conjugate vaccinePneumococcal VaccinesYoung Adultstomatognathic systemConjugate vaccineHeptavalent Pneumococcal Conjugate VaccinemedicineHumansTransplantation HomologousSeroconversionChildTransplantationGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthPneumococcal vaccineMiddle AgedAntibodies BacterialAllogeneic stem cell transplantationVaccinationInfectious DiseasesStreptococcus pneumoniaePneumococcal vaccineImmunologyMolecular MedicineFemalebusinessPneumococcal infectionmedicine.drugStem Cell Transplantation
researchProduct

Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza dur…

2013

Background: Since influenza predisposes to bacterial pneumonia caused by Streptococcus pneumoniae, studies have suggested that pneumococcal vaccination might reduce its occurrence during pandemics. We assessed the effectiveness of pneumococcal polysaccharide vaccination alone and in combination with influenza vaccination in preventing influenza hospitalization during the 2009–2010 pandemic wave and 2010–2011 influenza epidemic. Methods: We conducted a multicenter case-control study in 36 Spanish hospitals. We selected patients aged ≥ 18 y hospitalized with confirmed influenza and two hospitalized controls per case, matched according to age, date of hospitalization and province of residence.…

AdultMalemedicine.medical_specialtyAdolescentInfluenza vaccineImmunologymedicine.disease_causePneumococcal VaccinesYoung AdultInternal medicineStreptococcus pneumoniaePandemicInfluenza HumanmedicineImmunology and AllergyHumansYoung adultAgedPharmacologyAged 80 and overbusiness.industryBacterial pneumoniaCase-control studyvirus diseasesMiddle AgedPneumonia Pneumococcalmedicine.diseasePneumococcal polysaccharide vaccineVaccinationHospitalizationInfluenza VaccinesSpainCase-Control StudiesImmunologyCosts and Cost AnalysisFemalebusinessResearch Paper
researchProduct

Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical…

2006

Acute otitis media (AOM) is the most common bacterial infectious disease among children. Vaccination is proposed to prevent otitis and several clinical trials were performed to assess the efficacy of pneumococcal vaccines. The way vaccine efficacy is analysed varies among trials. However, the clinical meaning of an estimate of vaccine effect and its statistical test depends on the applied statistical method. We aim to bring the meaning and validity of statistical trial results to the attention of researchers. We consider all methodological approaches for analysing vaccine efficacy applied in pneumococcal vaccination trials included in a recent Cochrane Review. We demonstrate how different m…

medicine.medical_specialtyAcute otitis mediaPneumococcal InfectionsPneumococcal VaccinesmedicineHumansIntensive care medicineChildRandomized Controlled Trials as TopicGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryMiddle ear diseasePublic Health Environmental and Occupational HealthInfantVaccine efficacyClinical trialVaccinationOtitis MediaInfectious DiseasesOtitisInfectious disease (medical specialty)Research DesignChild PreschoolPneumococcal vaccinationImmunologyMolecular Medicinemedicine.symptombusinessVaccine
researchProduct

Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European Countries

1999

Pneumococcal vaccination of older persons is thought to be cost-effective in preventing pneumococcal pneumonia, but evidence of clinical protection is uncertain. Because there is better evidence of vaccination effectiveness against invasive pneumococcal disease, we determined the cost-effectiveness of pneumococcal vaccination of persons agedor =65 years in preventing hospital admission for both invasive pneumococcal disease and pneumococcal pneumonia in 5 western European countries. In the base case analyses, the cost-effectiveness ratios for preventing invasive disease varied from approximately 11,000 to approximately 33,000 European currency units (ecu) per quality-adjusted life year (QAL…

Microbiology (medical)medicine.medical_specialtyPediatricsCost effectivenessCost-Benefit AnalysisPneumococcal VaccinesmedicineHumansAgedAged 80 and overbusiness.industryIncidenceMortality rateIncidence (epidemiology)VaccinationPneumonia Pneumococcalmedicine.diseaseQuality-adjusted life yearSurgeryEuropeVaccinationPneumoniaInfectious DiseasesPneumococcal vaccinePneumococcal pneumoniaQuality-Adjusted Life YearsbusinessClinical Infectious Diseases
researchProduct